Androgen Reduction in Congenital Adrenal Hyperplasia
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to
have elevated circulating levels of androgens, which can accelerate skeletal maturation and
adversely impact adult height. Additionally, these children require supraphysiologic doses of
hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can
retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct
to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children
with classic 21-hydroxylase deficiency in order to reduce daily requirement of
hydrocortisone.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Children's Hospital Los Angeles Feinstein Institute for Medical Research National Institutes of Health Clinical Center (CC) University of Michigan